Wird geladen...

Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers - WO2010066840

This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Wulff, Heike
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2988097/
https://ncbi.nlm.nih.gov/pubmed/20954790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543776.2010.528392
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!